Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Pharma
Asia
Drug Delivery
Executives
Clinical Data
Vaccines
Special Reports
Trending
COVID-19
Cell & Gene Therapy
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Pharma
Asia
Drug Delivery
Executives
Clinical Data
Vaccines
Special Reports
Trending
COVID-19
Cell & Gene Therapy
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
eye diseases
Pharma
JPM: Novartis CEO refutes respiratory, eye drug sell-off report
Novartis is committed asthma drug Xolair and its eye disease portfolio, including gene therapies, CEO Vas Narasimhan said despite a sell-off rumor.
Angus Liu
Jan 9, 2023 4:56pm
Genentech starts phase 2 trial to optimize cell therapy delivery
Nov 28, 2022 10:20am
Apellis' closely watched eye drug gets new FDA goal date
Nov 18, 2022 12:03pm
Roche touts Vabysmo toe-to-toe data against Eylea in RVO
Oct 27, 2022 10:55am
Tarsus launches campaign for misdiagnosed eyelid condition
Sep 30, 2022 11:03am
Eylea set to battle back at Roche's Vabysmo
Sep 7, 2022 6:52pm